Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/- mice

A neutralizing antibody to the receptor for the advanced glycation end products (anti-RAGE Ab) was developed as a potential treatment of acute and chronic inflammatory conditions. Previous pharmacology studies demonstrated efficacy of the anti-RAGE antibody in a mouse model of sepsis. We examined pharmacokinetics and lung distribution of [I-125]anti-RAGE Ab in RAGE(-/-) and wild-type (129S5) mice following single IV administration. Serum pharmacokinetics of [I-125]anti-RAGE Ab was similar in RAGE(-/-) and 129S5 mice, with the total body clearance of 0.3 mL/hr/kg and the elimination half-life of 11-12 days, suggesting the target expression had limited impact on overall elimination of [I-125]anti-RAGE Ab from mice. [I-125]Anti-RAGE Ab accumulated in the lung of 129S5 mice, with similar to 4% of total dose retained in the lung at days 6-27 and the lung AUC(o-infinity) of similar to 300% of that in serum. The SDS-PAGE analysis suggested that most of retained lung radioactivity was attributed to intact antibody. No accumulation of radioactivity was observed in the lung of RAGE(-/-) mice, indicating that lung uptake of [I-125]anti-RAGE Ab was target-dependent in wild-type mice. These data suggest that the anti-RAGE Ab was able to localize to the site of RAGE expression, the lung, and support the findings in the previous pharmacology studies.